Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides

Trends in cancer(2021)10.1016/j.trecan.2020.12.012Source: DataRank Database

Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides is a research paper published in Trends in cancer (2021). On theSindex it has a DataRank of 0. It has been cited 76 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

76 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)Impact (FWCI 3.52)OA: closedTopics (48)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Takahiro Yamazaki ORCID,Erik Wennerberg ORCID,Baldur Sveinbjørnsson ORCID,Øystein Rekdal ORCID,Sandra Demaria ORCID

Live enrichment

PubMed:33446447 OpenAlex:https://openalex.org/W3120531579

U.S. Department of Defense

Grant: BC180595P1

National Cancer Institute

Grant: CA198533

National Cancer Institute

Grant: CA201246

Associazione Italiana per la Ricerca sul Cancro

Grant: IG 2017 20417

Breast Cancer Research Foundation

Grant: BCRF-20-053

EMD Serono

Stand Up To Cancer

Mersana Therapeutics

National Institutes of Health

Weill Cornell Medical College

Weill Cornell Medicine

Compagnia di San Paolo

Leukemia and Lymphoma Society

Boehringer Ingelheim

AstraZeneca

FWCI

3.52

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

2026

closedLicense: http://www.elsevier.com/open-access/userlicense/1.0/

publisherhttps://api.elsevier.com/content/article/PII:S2405803320303393?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2405803320303393?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.trecan.2020.12.012

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33446447

Fields of Study

Immunotherapy and Immune ResponsesVirus-based gene therapy researchRNA Interference and Gene DeliveryAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicDrug SynergismHumansImmune Checkpoint InhibitorsImmunogenic Cell DeathNeoplasmsPeptidesT-Lymphocytes, Cytotoxic

MeSH Terms

Immunogenic Cell DeathImmune Checkpoint InhibitorsAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDrug SynergismHumansNeoplasmsPeptidesT-Lymphocytes, CytotoxicClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicCell Line, Tumor

Keywords

Oncolytic virusImmune systemContext (archaeology)CancerCancer therapyImmunotherapyImmunityBiologyCancer cellCancer researchImmunologyComputational biologyMedicineInternal medicineGenomic instabilityNK cellsLL-37Ltx-315Cd8(+) Cytotoxic T LymphocytesAntimicrobial peptidesImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 0: Good health and well-being